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Abstract
The aim of the present work was to study the effect of angiotensin II (Ang II) on catecholamines and neuropeptide Y (NPY) release in
primary cultures of human adrenal chromaffin cells. Ang II stimulates norepinephrine (NE), epinephrine (EP) and NPY release from
perifused chromaffin cells by 3-, 2- and 12-fold, respectively. The NPY release is more sustained than that of catecholamines. We found that
the receptor-AT2 agonist, T2-(Ang II 4–8)2 has no effect on NE, EP and NPY release from chromaffin cells. We further showed that Ang II
increases intracellular Ca2 + concentration ([Ca2 +]i). The selective AT1-receptor antagonist Candesartan blocked [Ca
2 +]i increase by Ang II,
while T2-(Ang II 4–8)2 was ineffective. These findings demonstrate that AT1 stimulation induces catecholamine secretion from human
adrenal chromaffin cells probably by raising cytosolic calcium.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
It is well established that angiotensin II (Ang II) is able to
stimulate catecholamine release from bovine, rat and porcine
adrenal chromaffin cells [1–7]. However, controversy exists
about whether AT1 or AT2 receptors are involved in this effect
in several species [6–12]. No study is available to clearly
demonstrate, in vitro, the effect of Ang II on human adrenal
medulla on catecholamine release since this subject has been
debated almost 40 years ago [13]. Neuropeptide Y (NPY) is a
36-amino-acid peptide present in the adrenal medulla of
many species, including humans [14–16] and is co-localized
with catecholamines in the same granules [17]. Functionally,
NPYpotentiates the effect of various agonists such as Ang II
and norepinephrine (NE) in addition to exerting a direct
contractile effect on the vasculature [18]. We have previously
found that NPY, like nicotine, increases catecholamine
release from human chromaffin cells through the NPY y3
receptor [19]. The aim of this work was to study the effects of
Ang II on NE, epinephrine (EP) and NPY secretions in
human adrenal chromaffin cells in culture.
2. Materials and methods
2.1. Peptides and antagonists
Angiotensin II was purchased from Novabiochem (Lau-
felfingen, Switzerland). T2-(Ang II 4–8)2 is a template-
assembled peptide agonist for AT2 receptors made of two
angiotensin II 4–8 pentapeptide fragments (Ang II 4–8)2,
attached to a carrier molecule (T2) which alone did not bind
to either AT1 or AT2 receptors. Binding assays showed that in
the presence of an AT1 antagonist, T2-(Ang II 4–8)2 com-
pletely inhibited the specific binding of 125I-AII to the AT2
receptors of a rat adrenal membrane preparation and that
half-maximal inhibition (IC50) occurred at the concentration
of 2 10 7 M. In contrast, T2-(Ang II 4–8)2 at the concen-
tration of 10 5 M did not bind to AT1 receptors of rat aortic
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smooth muscle cells. T2-(Ang II 4–8)2 mediates an agonistic
angiotensin II effect on neurones of the inferior olive that
express only AT2 receptors [20]; the AT1 antagonist Cande-
sartan was obtained from Astra-Zeneca (Molndal) [21].
2.2. Adrenal glands and cell culture
The study was approved by the Hospital Transplantation
Review Board and by the Medical Direction. For these
studies, adrenal glands were obtained from four kidney
transplant donors. All the donors were brain dead patients
whose relatives had accepted multiorgan procurement.
Chromaffin cells were isolated by the procedure described
previously [19]. We shown that such preparation with
differential plating allowed to obtain at least 95% pure
chromaffin cell in culture.
2.3. Assay of [Ca2+]i
Intracellular free calcium concentration ([Ca2 +]i) was
determined using the fluorescent probe fluo-3/AM (Mole-
cular Probes) as previously described [22]. Cells were
preincubated for 2 min with the AT1 antagonist Candesartan
(1 AM) prior the addition of Ang II.
2.4. Release experiments
Cells were plated on glass coverslips placed in a peri-
fusion chamber warmed at 37 jC and stabilized for 90 min
at a flow rate of 0.35 ml/min with Krebs buffer (KB). The
drugs were administered in KB as a prolonged infusion.
Samples were then collected alternately every 2 min for
NPY and catecholamine assays [19]. At the end of the
perifusion, the coverslips were recovered and the cells lyzed
with 0.5 ml of 0.4 M perchloric acid and sonicated. After
centrifugation, an aliquot of supernatant was used to meas-
ure catecholamines and NPY. Catecholamines (NE and EP)
were determined by HPLC with electrochemical detection
(Waters, Milford, MA) [23]. NPY concentrations were
measured by enzyme immunoassay [24].
2.5. Statistical methods
All values are expressed as meanF S.E.M.. The data
were compared by one-way analysis of variance with post
hoc analysis using Student’s unpaired t-test according to
Bonferroni’s method.
3. Results
3.1. Angiotensin II stimulates catecholamine and NPY
secretions
In perifused chromaffin cells, catecholamines and NPY
are constitutively released (Fig. 1A). NE, EP and NPY are
Fig. 1. Effect of AT2 agonist, Ang II and KCl on basal release of NE, EP and
NPY from human adrenal chromaffin cells. Cells were perifused for 20 min
with KB followed by 20 min with 500 nM AT2 agonist, 30 min with KB, 20
min with 100 nM Ang II, 14 min with KB and 16 min with 56 mM KCl.
Every 2 min, perifusion samples were collected alternatively for NPY and
for catecholamines assays. (A) Release of NE, EP and NPY is expressed as
% of the intracellular content. Amount of NPY (B) and NE and EP (C)
released per minute. One representative experiment of three is shown.
Fig. 2. Angiotensin II 100 nM increases [Ca2 +]i in human adrenal
chromaffin cells. Typical trace taken from the recording of a single
chromaffin cell loaded with fluo-3/AM and exposed with Ang II.
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secreted at a rate of 0.08F 0.01%, 0.07F 0.007% and
0.07F 0.008% of intracellular content/2 min, respectively.
The AT2 agonist T2-(Ang II 4–8)2 (500 nM) infusion for
20 min had no effect on catecholamine, and NPY release
by chromaffin cells with NE, EP and NPY are secreted at a
rate of 0.06F 0.01%, 0.07F 0.008% and 0.06F 0.003% of
intracellular content/2 min, respectively. Chromaffin cells
constitutively released similar amounts of NE and EP
representing 53% of total catecholamine secreted. In con-
trast, Ang II (100 nM) infusion for 20 min increased the
release of both NPY and catecholamines by about 12- and
3-fold, respectively (Fig. 1B and C). Ang II produced a
higher increase of NE secretion compared to the one
observed for EP; therefore, AngII caused a preferential
release of secretory granules that contain NE over those
that are filled with EP or NPY, representing 80% of total
catecholamine secreted.
The pattern of secretion is divided into two phases; a
few seconds after exposure to Ang II, NE, EP and NPY
were secreted apparently simultaneously with a peak at 4–
6 min. However, NE and EP secretion returned to basal
levels within 10 min after the addition of Ang II, whereas
10 min after removal of Ang II, NPY secretion rate was
still higher than basal release (Fig. 1A). KCl was the most
potent stimulus for catecholamine and NPY secretion (Fig.
1A).
3.2. Signal transduction induced by angiotensin II receptors
in chromaffin cells
Next, we examined the pharmacology of functional Ang
II receptors expressed on individual human chromaffin
cells by measuring [Ca2 +]i increases evoked by Ang II,
the AT2 agonist T2-(Ang II 4–8)2 and Ang II after
preincubation of the chromaffin cells with 1 AM Cande-
sartan, an AT1 antagonist. Ang II induced an increase in
[Ca2 +]i peaking in 20 s followed by a rapid decrease
within 30 s (Fig. 2). The basal [Ca2 +]i level was 127F 12
nM (n = 306). Ang II at 10 and 100 nM concentrations
caused a similar mean increase in [Ca2 +]i of 68F 18 and
59F 16 nM, respectively (Table 1). Ang II stimulated 47%
of the cells at 10 nM and 30% at 100 nM. Interestingly,
when we take into account the responding cells, we found
a stronger increase in [Ca2 +]i with the highest dose of Ang
II. We did not observe any changes in calcium cytosolic
concentrations when the cells were preexposed to Cande-
sartan for 2 min, but the calcium response to 10 nM Ang
II was strongly attenuated (only 10% of responding cells)
increasing 7F 4 nM the [Ca2 +]i (Table 1). In addition, the
AT2 agonist T2-(Ang II 4–8)2 (100 nM) had no effect on
[Ca2 +]i (Table 1).
4. Discussion
Numerous lines of evidence indicate that Ang II stim-
ulates catecholamine secretion from the adrenal medulla of
several species [1–7]. However, the involvement of AT1
and AT2 receptors in such effect is also dependent on the
animal species studied [6–12]. It has been shown that
cultured porcine chromaffin cells secreted catecholamines
in response to an AT2 agonist [9], whereas other studies
have shown that Ang II increases catecholamine release
from bovine chromaffin cells through functionally active
AT1 receptors [12]. Interestingly, some investigations
reported mixed population of Ang II receptors in adrenal
medulla depending on the species studied; for instance,
AT2 receptors accounted for 95% of Ang II binding sites
in rat adrenal medulla, and 5% of the remaining binding
sites were AT1 [14]. Binding experiments are in agreement
with functional studies since the AT2 receptor agonist
CGP42112 induced catecholamine release from the rat
adrenal medulla and the effect of Ang II was markedly
inhibited by the AT2 antagonist PD123319, but was not
affected by the AT1 antagonist Losartan [7]. However, a
slight inhibitory effect of Losartan on catecholamine
release evoked by Ang II indicated that AT1 receptors
could be partially involved [7]. Indeed, another study
reported that the catecholamine release from rat adrenal
medulla was mainly mediated by AT1 stimulation linked to
an increase in cytosolic calcium concentrations [6]. The
exact subtype of Ang II receptor(s) in human adrenal
medulla is not clearly established since one study reports
that mRNA encoding for the AT1 receptor predominates
(85%) over the AT2 receptor (15%) [10], whereas contra-
dictory autoradiographic studies reveal that AT2 receptors
are found mainly in the medulla [11]. We have previously
shown that AT1 receptors are transcribed and translated in
functional proteins in a human pheochromocytoma and
that Ang II increases intracellular calcium and induces a
dose-dependent secretion of NE and NPY in pheochromo-
cytes [25]. Our present findings demonstrate that Ang II
Table 1
[Ca2 +]i in human adrenal chromaffin cells
D[Ca2 +]i (nM)
in all cells
D[Ca2 +]i (nM)
responding cells
% of
responding cells
Ang II (100 nM)
(n= 156)
59F 16 218F 58 30
Ang II (10 nM)
(n= 68)
68F 18 144F 34 47
Ang II (10 nM) +
Candesartan
(1 AM) (n= 72)
7F 4*** 84F 41 10
AT2 agonist
(100 nM) (n= 33)
0 0 0
Data were obtained from four different glands. n is the total number of cells
undergoing individual calcium measurement. Responding cells represent
the proportion of cells that increase their free cytosolic calcium by at least
10 nM. Candesartan (1 AM) was added 2 min before Ang II 10 nM. AT2
agonist used was T2-(Ang II 4–8)2. Data are expressed as the mean -
F S.E.M. increase in [Ca2 +]i.
***p< 0.001 compared to Ang II 10 nM.
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increases catecholamine secretion on human chromaffin
cells through the AT1 receptor since our AT2 agonist was
ineffective. Therefore, we used a high concentration of T2-
(AngII 4–8)2 (500 nM) far above the IC50 (190 nM) on
AT2 receptor to ensure that the peptidomimetic occupied
90% of the binding site available in a preparation of cells
expressing the AT2 receptor [26]. Unfortunately, the cel-
lular effects linked to AT2 stimulation are generally diffi-
cult to be demonstrated and despite the lack of positive
control for our AT2 agonist with chromaffin cells, this
molecule has proven to be active in various models where
the AT2 receptor was involved [20,21]. We observed a
preferential secretion of NE rather than EP in response to
Ang II, suggesting that stimulus-secretion coupling of the
exocytic machinery may be different for EP- and NE-
containing cells as previously found in bovine chromaffin
cells [27]. The fact that the AT1 antagonist Candesartan
blocked the Ang II-induced [Ca2 +]i mobilization estab-
lishes that the link between transduction and secretion
occurred via the AT1 receptor. The finding that Ang II
evokes a simultaneous release of NPY, EP and NE is in
favor of a common storage of NPY within NE and/or EP
granules; moreover, the long-lasting secretion of NPY even
after the end of Ang II infusion might reflect the existence
of a distinct pool of granules containing mainly NPY. We
previously observed the same phenomenon when nicotine
was used as a secretagogue [19]. Since NPY released from
the adrenal medulla could locally enhances the secretion of
catecholamine through a autocrine/paracrine mechanism
[19], we postulated that the Ang II-induced NPY secretion
also contributes to enhance a sustain secretion of catechol-
amine.
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